ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.81
+1.38 (5.89%)
Mar 9, 2026, 4:00 PM EDT - Market closed
ArriVent BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 45.54 | 74.29 | 150.39 | 163.37 | 37.28 |
| Short-Term Investments | 267.28 | 144.57 | - | - | - |
| Cash & Short-Term Investments | 312.82 | 218.86 | 150.39 | 163.37 | 37.28 |
| Cash Growth | 42.93% | 45.53% | -7.95% | 338.23% | - |
| Other Receivables | - | 0.5 | 0.76 | 0.5 | 0.25 |
| Receivables | - | 0.5 | 0.76 | 0.5 | 0.25 |
| Prepaid Expenses | 0.19 | 0.41 | 0.37 | 0.33 | 0.03 |
| Other Current Assets | 19.89 | 7.21 | 8.45 | 18.42 | 5.39 |
| Total Current Assets | 332.9 | 226.98 | 159.97 | 182.62 | 42.95 |
| Property, Plant & Equipment | 0.01 | 0.15 | 0.29 | 0.14 | - |
| Long-Term Investments | - | 47.68 | - | - | - |
| Long-Term Deferred Charges | 0.07 | - | 2.73 | - | - |
| Other Long-Term Assets | 0.19 | 0.13 | 0.11 | 0.07 | 0.09 |
| Total Assets | 333.17 | 274.94 | 163.1 | 182.83 | 43.04 |
| Accounts Payable | 5.93 | 3.78 | 4.53 | 3.09 | 0.29 |
| Accrued Expenses | 20 | 13.33 | 6.95 | 5.14 | 1.53 |
| Current Portion of Leases | 0.01 | 0.16 | 0.14 | 0.13 | - |
| Total Current Liabilities | 25.95 | 17.27 | 11.62 | 8.36 | 1.82 |
| Long-Term Leases | - | 0.01 | 0.18 | 0.01 | - |
| Total Liabilities | 25.95 | 17.29 | 11.8 | 8.37 | 1.82 |
| Common Stock | 0 | 0 | - | - | - |
| Additional Paid-In Capital | 711.85 | 496.2 | 4.65 | 3.4 | 2.96 |
| Retained Earnings | -404.64 | -238.33 | -157.85 | -88.51 | -51.61 |
| Comprehensive Income & Other | 0.01 | -0.21 | - | - | -0 |
| Total Common Equity | 307.22 | 257.65 | -153.19 | -85.11 | -48.64 |
| Shareholders' Equity | 307.22 | 257.65 | 151.3 | 174.46 | 41.22 |
| Total Liabilities & Equity | 333.17 | 274.94 | 163.1 | 182.83 | 43.04 |
| Total Debt | 0.01 | 0.18 | 0.32 | 0.14 | - |
| Net Cash (Debt) | 312.81 | 218.69 | 150.07 | 163.23 | 37.28 |
| Net Cash Growth | 43.04% | 45.72% | -8.06% | 337.86% | - |
| Net Cash Per Share | 8.13 | 6.95 | 70.10 | 127.82 | 52.42 |
| Filing Date Shares Outstanding | 44.2 | 34.02 | 33.49 | 31.96 | 0.71 |
| Total Common Shares Outstanding | 42.45 | 33.71 | 2.75 | 2.6 | 0.71 |
| Working Capital | 306.95 | 209.71 | 148.34 | 174.26 | 41.13 |
| Book Value Per Share | 7.24 | 7.64 | -55.80 | -32.76 | -68.40 |
| Tangible Book Value | 307.22 | 257.65 | -153.19 | -85.11 | -48.64 |
| Tangible Book Value Per Share | 7.24 | 7.64 | -55.80 | -32.76 | -68.40 |
Source: S&P Capital IQ. Standard template. Financial Sources.